1
|
Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B, Li D, Sun Z, Li Y, He Y, Ma L, Gao S, Hu J, He A, Du X, Liu D, Zhang X, Ke X, Zhuang J, Han Y, Wang X, Chen Y, Gordon P, Yu D, Zugmaier G, Wang J. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. HEMATOLOGY (AMSTERDAM, NETHERLANDS) 2022; 27:917-927. [PMID: 36000952 DOI: 10.1080/16078454.2022.2111992] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES The prognosis for adults with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is poor. Blinatumomab is a CD3/CD19-directed BiTE® (bispecific T-cell engager) molecule approved globally for the treatment of BCP-ALL in adults and children. This multicenter open-label single-arm China registrational study evaluated the safety, efficacy, and pharmacokinetics of blinatumomab in Chinese adults with Philadelphia chromosome-negative (Ph-) R/R BCP-ALL (NCT03476239). METHODS Patients aged ≥ 18 years were treated with up to 5 cycles of blinatumomab. The primary objective was to evaluate the hematological response rate (complete remission/complete remission with partial hematological recovery [CR/CRh]) within 2 cycles of blinatumomab. RESULTS At the interim analysis (April 12, 2019), 90 patients (median age 31.5 years [range: 18-74]; 53.3% female; 77.8% with bone marrow blasts ≥ 50% at study entry) were enrolled at 23 study centers in China and had received blinatumomab. As of data cutoff, 43 patients (47.8%) continued the study. The CR/CRh rate within 2 cycles of blinatumomab was 45.6% (41/90 [CR, 37; CRh, 4]; 95% CI: 35.0-56.4). Median overall survival was 9.2 months (95% CI: 6.5-11.7); median relapse-free survival was 4.3 months (95% CI: 3.2-9.4). Mean serum concentration at steady-state and systemic clearance of blinatumomab in Chinese patients were within the range reported in adults from global clinical trials. No new safety risks were identified in Chinese patients. CONCLUSIONS The efficacy and safety of blinatumomab in these heavily pre-treated Chinese patients with Ph- R/R BCP-ALL is comparable to that for patients within global clinical trials.
Collapse
Affiliation(s)
- Hongsheng Zhou
- Nanfang Hospital, Southern Medical University, Guangzhou, China
| | | | - Jie Jin
- The First Affiliated Hospital, College of Medicine, Zhejiang University College of Medicine, Hangzhou, China
| | - Ting Liu
- West China Hospital, Sichuan University, Chengdu, China
| | - Zhen Cai
- The First Affiliated Hospital, College of Medicine, Zhejiang University College of Medicine, Hangzhou, China
| | - Bin Jiang
- Peking University International Hospital, Beijing, China
| | - Dengju Li
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | - Zimin Sun
- Anhui Provincial Hospital, Hefei, China
| | - Yan Li
- The First Hospital of China Medical University, Shenyang, China
| | - Yanjuan He
- Xiangya Hospital Central South University, Changsha, China
| | - Liping Ma
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Sujun Gao
- The First Hospital of Jilin University, Jilin, China
| | - Jianda Hu
- Fujian Medical University Union Hospital, Fujian, China
| | - Aili He
- The Second Affiliated Hospital of Xian Jiaotong University, Shaanxi, China
| | - Xin Du
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Daihong Liu
- Chinese People Liberation Army General Hospital, Beijing, China
| | - Xiaohong Zhang
- The Second Affiliated Hospital Zhejiang University College of Medicine, Zhejiang, China
| | - Xiaoyan Ke
- Peking University Third Hospital, Beijing, China
| | | | - Yue Han
- The First Affiliated Hospital of Soochow University, Jiangsu, China
| | - Xiaoqin Wang
- Huashan Hospital Affiliated to Fudan University, Shanghai, China
| | - Yuqi Chen
- Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA
| | - Paul Gordon
- Global Development, Amgen Inc., Thousand Oaks, CA, USA
| | - Dong Yu
- Amgen China, Shanghai, People's Republic of China
| | - Gerhard Zugmaier
- Global Development, Amgen Research (Munich) GmbH, Munich, Germany
| | - Jianxiang Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China
| |
Collapse
|
2
|
Fujishima N, Uchida T, Onishi Y, Jung CW, Goh YT, Ando K, Wang MC, Ono C, Matsumizu M, Paccagnella ML, Sleight B, Vandendries E, Fujii Y, Hino M. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. Int J Hematol 2019; 110:709-722. [PMID: 31655984 DOI: 10.1007/s12185-019-02749-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 09/24/2019] [Accepted: 09/25/2019] [Indexed: 12/14/2022]
Abstract
Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3 trial comparing InO against standard of care (SoC). In the present subgroup analysis, we evaluated outcomes in the 55 Asian patients who were randomized in INO-VATE (31 InO and 24 SoC). Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 22/31 patients treated with InO versus 5/24 treated with SoC. In the InO arm, more of the patients achieving CR/CRi were minimal residual disease (MRD)-negative (17/22 versus 1/5), and more patients proceeded directly to hematopoietic stem cell transplantation (15/31 versus 3/24). Median overall survival for the respective arms was 5.8 versus 3.9 months (hazard ratio 0.67; 97.5% CI 0.28, 1.62). In the safety analysis (n = 51), the most common adverse events were hematologic. Sinusoidal obstruction syndrome was reported in five InO patients and one SoC patient. In conclusion, Asian patients with relapsed or refractory B-cell ALL experienced improved efficacy with InO versus SoC, with an efficacy and safety profile consistent with results of the overall INO-VATE population.Clinical trial registration: ClinicalTrials.gov identifier: NCT01564784.
Collapse
Affiliation(s)
- Naohito Fujishima
- Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, 1-1-1, Hondo, Akita, 010-8543, Japan.
| | | | | | | | - Yeow Tee Goh
- Singapore General Hospital, Bukit Merah, Singapore
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Straiton J. Welcome to Volume 8 of the International Journal of Hematologic Oncology. Int J Hematol Oncol 2019; 8:IJH11. [PMID: 30863528 PMCID: PMC6410014 DOI: 10.2217/ijh-2018-0012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 12/11/2018] [Indexed: 11/27/2022] Open
Affiliation(s)
- Jennifer Straiton
- Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK
| |
Collapse
|